Next-Generation Precision Gene Editing & Genetic Therapies
Leveraging targeted CRISPR platforms to engineer novel cell therapies and address critical unmet needs in life sciences.
Inquire for Institutional Access
About the Platform
Dhumi Labs is a US-backed biotechnology company advancing a proprietary genetic engineering platform. Our R&D initiative focuses on optimizing CRISPR delivery mechanisms and molecular assay development to accelerate discovery pipelines from target identification to pre-clinical validation.
Target Identification
Genomic screening to pinpoint high-value loci.
Platform Optimization
Tuning delivery vectors and editing efficiency.
Validation
Pre-clinical in-vitro efficacy and safety readouts.
Core Capabilities
Targeted Gene Editing
Designing specialized guide RNA constructs and Cas variants for high-specificity genomic targeting.
Molecular Validation
High-throughput cellular assay design, Next-Generation Sequencing (NGS) preparation, and expression profiling.
Translational Pipeline
Building robust in-vitro models to validate target efficacy and safety profiles under BSL-2 standards.
Expanding Global R&D Footprint
BSL-2 Wet-Lab Compliance
Facilities and protocols aligned to Biosafety Level 2 standards for genetic engineering work.
Core Activities
Molecular biology, mammalian cell culture, and assay optimization workflows.
Scientific Leadership
A team led by US & Indian PhD researchers bridging two innovation ecosystems.
US-Backed Governance
Operating under US venture oversight with institutional partner reporting.
Institutional & Collaboration Inquiries
For incubator management, institutional partners, and talent inquiries.